Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer

Recent therapeutic advances for managing advanced prostate cancer include the successful targeting of the androgen-AR axis with several new drugs in castrate resistant prostate cancer including abiraterone acetate and enzalutamide (MDV3100). This translational progress from “bench to bed-side” has r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohli, Manish, Qin, Rui, Jimenez, Rafael, Dehm, Scott M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432332/
https://www.ncbi.nlm.nih.gov/pubmed/22956944
http://dx.doi.org/10.1155/2012/781459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432332/
https://www.ncbi.nlm.nih.gov/pubmed/22956944
http://dx.doi.org/10.1155/2012/781459

Ejemplares similares